APP and Alzheimer disease: [11C]CPPC was developed from a potent CSF1R inhibitor with an IC50 of 0.8 nM (Horti et al., 2019) and evaluated in a mouse model of AD-related amyloidosis-overexpressing APP with Swedish and Indiana mutations (Melnikova et al., 2013).